Results 151 to 160 of about 1,948,666 (273)

Atherosclerosis: From Pathogenesis to Therapeutic Interventions

open access: yesMedComm, Volume 7, Issue 11, November 2026.
The diagram outlines the core mechanisms driving atherosclerosis, including endothelial dysfunction, inflammatory responses, phenotypic switching of smooth muscle cells, and the gut–vascular axis. It also presents the corresponding therapeutic approaches now under development, such as gene therapies, immunotherapies, and nanotechnology platforms ...
Enge Zhou   +9 more
wiley   +1 more source

Exercise‐Based Management of Diabetic Cardiomyopathy: Preclinical Mechanisms, Clinical Evidence, and Translational Strategies

open access: yesJournal of Diabetes, Volume 18, Issue 11, November 2026.
Exercise may mitigate diabetic cardiomyopathy by improving mitochondrial metabolism, redox balance, calcium handling, and inflammatory‐fibrotic remodeling. Translation into clinical practice requires phenotype‐ and risk‐adapted exercise prescriptions, standardized dose reporting, and multimodal monitoring to define safety, efficacy, and long‐term ...
Xiaoya Li, Zhiqiang Wang, Jingjing Liu
wiley   +1 more source

Treatment progression in sulfonylurea and dipeptidyl peptidase-4-inhibitor cohorts of type 2 diabetes patients on metformin

open access: yes, 2016
Xiaomei Peng, Dingfeng Jiang, Dongju Liu, Oralee J Varnado, Jay P Bae Eli Lilly and Company, Global Patient Outcomes and Real World Evidence, Indianapolis, IN, USA Background: Metformin is an oral antidiabetic drug (OAD) widely used as first-line ...
Peng X   +4 more
core  

Continuous Glucose Monitoring‐Derived Glycemic Phenotypes Reflect Metabolic Heterogeneity Linked to Advanced Cardiovascular‐Kidney‐Metabolic Syndrome in Older Adults With Type 2 Diabetes

open access: yesJournal of Diabetes, Volume 18, Issue 11, November 2026.
In 2491 older adults with Type 2 diabetes, four continuous glucose monitoring‐derived glycemic phenotypes reflected metabolic heterogeneity. Despite not having the highest HbA1c, the phenotype with high hyperglycemic burden and low glycemic variability showed greater insulin resistance and the largest point estimate of association with advanced ...
Hang Su   +8 more
wiley   +1 more source

Quality of Diabetes Care Among Older Adults in Germany—Results of the Study on Health of Older People 2022/2023 Compared With Previous National Health Surveys

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10018-10027, November 2026.
ABSTRACT Aims The study aims (1) to evaluate the quality of diabetes care considering guideline‐recommended medical therapies, cardiometabolic factors, and self‐management of health behaviours among older adults with diabetes in Germany, and (2) to examine time trends.
Yong Du   +6 more
wiley   +1 more source

Bowel Obstruction/Ileus Associated With the Use of Glucagon‐Like Peptide‐1 Receptor Agonists: A Nationwide Database Study

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 9941-9954, November 2026.
ABSTRACT Aims The association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP‐1RA use and the incidence of bowel obstruction/ileus subtypes across different ...
Yuichiro Matsuo   +3 more
wiley   +1 more source

Oleanolic Acid‐Enriched Olive Oil Attenuates Kidney Function Decline in Patients With Type 2 Diabetes: Results From the OLTRAD Randomised Controlled Trial

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10195-10209, November 2026.
ABSTRACT Aims Chronic kidney disease (CKD) is a major complication of type 2 diabetes mellitus (T2DM), driven in part by oxidative stress and the accumulation of advanced glycation end products (AGEs). Oleanolic acid (OA), a natural triterpene present in olive‐derived matrices, may modulate AGE metabolism.
Aída García‐González   +14 more
wiley   +1 more source

Association of GLP‐1 Receptor Agonist Use With Cardiovascular Outcomes and Mortality in Japanese Patients With Type 2 Diabetes: A Real‐World Claims Database Study

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10037-10044, November 2026.
ABSTRACT Aims Large‐scale clinical trials have shown multiple effects of glucagon‐like peptide 1 receptor agonists (GLP‐1RAs); however, similar evidence for Asian patients is limited. Therefore, using a Japanese large‐scale claims‐based database, the effects of GLP‐1RAs on cardiovascular and cerebrovascular events including mortality were compared with
Masaya Koshizaka   +7 more
wiley   +1 more source

Person‐Reported and Continuous Glucose Monitoring (CGM) Recorded Hypoglycaemia in People With Insulin‐Treated Type 2 Diabetes and Mild to Moderate Chronic Kidney Disease; Post Hoc Analysis From the Hypo‐METRICS Study

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10664-10669, November 2026.
ABSTRACT Background and Aims People with diabetes and chronic kidney disease (CKD) may be at increased risk of iatrogenic hypoglycaemia. We compared rates of sensor‐detected (SDH) and person‐reported hypoglycaemia (PRH) in people with insulin‐treated Type 2 diabetes (T2D) with and without CKD in the Hypo‐METRICS study.
Julie M. B. Brøsen   +39 more
wiley   +1 more source

Exploratory Analysis of Type 2 Diabetes Mellitus Metabolic Phenotypes and Their Association With Vitamin D Status in Primary Care Patients

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10603-10614, November 2026.
ABSTRACT Aims This study aimed to perform an exploratory characterisation of metabolic phenotypes in primary care patients with type 2 diabetes mellitus (T2DM), using a predefined approach and examine their association with vitamin D status. Materials and Methods This cross‐sectional study included 178 participants randomly selected in Sergipe, Brazil.
Liliane Viana Pires   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy